Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.
Asian Pac J Cancer Prev. 2021 May 1;22(5):1607-1611. doi: 10.31557/APJCP.2021.22.5.1607.
An accurate assessment of potential pathologic complete response(pCR) following neoadjuvant chemoradiotherapy(NCRT) is important for the appropriate treatment of rectal cancer. However, the factors that predict the response to neoadjuvant chemoradiotherapy have not been well defined. Therefore, this study analyzed the predictive factors on the development of pCR after neoadjuvant chemoradiation for rectal cancer.
From January 2008 to January 2018, a total of 432 consecutive patients from a single institution patients who underwent a long-course neoadjuvant chemoradiotherapy were reviewed in this study. The clinicopathological features were analyzed to identify predictive factors for pathologic complete response in rectal cancer after neoadjuvant chemoradiation.
The rate of pathologic complete response in rectal cancer after neoadjuvant chemoradiation was 20.8%, patients were divided into the pCR and non-pCR groups. The two groups were well balanced in terms of age, gender, body mass index, ASA score, tumor stage, tumor differentiation, tumor location, surgical procedure, chemotherapy regimen and radiation dose. The multivariate analysis revealed that a pretreatment carcinoembryonic antigen (CEA) level of ≤5 ng/mL and an interval of ≥8 weeks between the completion of chemoradiation and surgical resection were independent risk factors of an increased rate of pCR.
Pretreatment carcinoembryonic antigen (CEA) level of ≤5 ng/mL and an interval of ≥8 weeks between the completion of chemoradiation and surgical resection are predictive factors for pathologic complete response in rectal cancer after neoadjuvant chemoradiation. Using these predictive factors, we can predict the prognosis of patients and develop adaptive treatment strategies. A wait-and-see policy might be possible in highly selective cases.
新辅助放化疗(NCRT)后潜在病理完全缓解(pCR)的准确评估对直肠癌的适当治疗很重要。然而,预测新辅助放化疗反应的因素尚未得到很好的定义。因此,本研究分析了新辅助放化疗后直肠癌 pCR 发展的预测因素。
本研究回顾了 2008 年 1 月至 2018 年 1 月期间来自一家机构的 432 例连续接受长疗程新辅助放化疗的患者。分析了临床病理特征,以确定新辅助放化疗后直肠癌病理完全缓解的预测因素。
新辅助放化疗后直肠癌的病理完全缓解率为 20.8%,患者分为 pCR 组和非 pCR 组。两组在年龄、性别、体重指数、ASA 评分、肿瘤分期、肿瘤分化、肿瘤部位、手术方式、化疗方案和放疗剂量方面均平衡良好。多因素分析显示,治疗前癌胚抗原(CEA)水平≤5ng/ml 和放化疗完成与手术切除之间的间隔时间≥8 周是 pCR 发生率增加的独立危险因素。
治疗前癌胚抗原(CEA)水平≤5ng/ml 和放化疗完成与手术切除之间的间隔时间≥8 周是新辅助放化疗后直肠癌病理完全缓解的预测因素。使用这些预测因素,我们可以预测患者的预后,并制定适应性治疗策略。在高度选择的情况下,可能可以采取观望政策。